Reduction in Serum High-Sensitivity C-Reactive Protein Favors Kidney Outcomes in Patients with Impaired Fasting Glucose or Diabetes
Table 2
Hazard ratios (HRs) and 95% CIs for kidney outcomes.
No reduction in hs-CRP levels
Reduction in hs-CRP levels
Outcome 1 (): kidney function decline
Number of patients
2309
1596
Number of events
259 (11.2%)
139 (8.7%)
Per 100,000 person-years
2308
1659
Model 1, HR (95% CI)
Reference
0.73 (0.59, 0.90)
—
0.003
Model 2, HR (95% CI)
Reference
0.71 (0.57, 0.89)
—
0.002
Sensitivity analysis (), HR (95% CI)
Reference
0.69 (0.54, 0.87)
—
0.002
Outcome 2 (): development of proteinuria
Number of patients
1131
918
Number of events
182 (16.1%)
115 (12.5%)
Per 100,000 person-years
3278
2451
Model 1, HR (95% CI)
Reference
0.72 (0.57, 0.92)
—
0.008
Model 2, HR (95% CI)
Reference
0.77 (0.61, 0.99)
—
0.038
Sensitivity analysis (), HR (95% CI)
Reference
0.77 (0.59, 1.00)
—
0.053
Outcome 3 (): progression of proteinuria
Number of patients
328
165
Number of events
33 (10.1%)
14 (8.5%)
Per 100,000 person-years
2154
1672
Model 1, HR (95% CI)
Reference
0.83 (0.43, 1.60)
—
0.575
Model 2, HR (95% CI)
Reference
0.95 (0.48, 1.88)
—
0.885
Note: in all three outcomes, model 1 was adjusted for age and sex; model 2 further controlled for BMI, WC, FBG, dyslipidemia, hypertension, antihypertensive drugs, hyperuricemia, cigarette use, drinking, physical exercise, and eGFR. In outcome 1, add proteinuria.
